USFDA May Relax Biosimilar Testing Requirements, Development Costs Could Drop by USD 20 Million
Bengaluru: The U.S. Food ​and Drug Administration ​plans to ease testing requirements for ​companies developing biosimilar drugs, Bloomberg News reported, citing an agency official and internal documents.The FDA is ‌expected…